Tozasertib

Drug Profile

Tozasertib

Alternative Names: MK-0457; VX-680

Latest Information Update: 20 Aug 2008

Price : $50

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Merck & Co
  • Class Antineoplastics; Piperazines; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors; Bcr-abl tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Haematological malignancies; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 03 Jun 2008 Preclinical pharmacodynamics data of combination of tozasertib with vorinostat in Chronic myeloid leukaemia presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 20 Nov 2007 Merck & Co suspends patient enrollment in clinical trials of tozasertib until full analysis of clinical data can be conducted
  • 04 Jan 2007 Data presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH-2006) added to the adverse events and Cancer therapeutic trials and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top